Tradestie Institutional Equity Comparison Engine

MEDI vs DNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MEDI Overall Edge

MEDI Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harbor Health Care ETF (MEDI) driven by superior Momentum & Technical, Options & Structure while DNA counters with relative strength in Growth & Margin. Fundamentally, MEDI trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus DNA at N/M Forward P/E and -202.5% operating margin (-5.7% YoY). In options structure, MEDI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DNA sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MEDI N/M vs DNA N/M Fwd P/E
Growth & Margin Winner DNA
Op Margin N/A vs -202.5% ยท YoY N/A vs -5.7%
Momentum & Technical Winner MEDI
1Y +14.7% vs +6.2% ยท 52W Pos 90% vs 24%
Options & Structure Winner MEDI
UNCLASSIFIED (N/A IV) vs BREAKDOWN (34th %ile IV)
MEDI NYSE Arca
Harbor Health Care ETF
Institutional Equity
$35.59
-2.05% 1D
Market Cap N/A
1M Return +9.92%
1Y Return +14.68%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 22.2
DNA NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap $623.0M
1M Return -17.23%
1Y Return +6.25%
Forward P/E N/M
Unified AI Score
57.4 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MEDI +14.68% DNA +6.25% Spread: +8.43 pp (MEDI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MEDI TTM Op. Margin: N/A DNA TTM Op. Margin: -202.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MEDI vs DNA. Trailing 12-month operating profitability (MEDI N/A vs DNA -202.5%) and valuation multiples (MEDI N/M vs DNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MEDI (2) vs DNA (6)
Institutional Metric MEDI DNA Criterion Row Winner
Market Capitalization Scale N/A $623.0M Larger Scale DNA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A -5.7% Higher Growth DNA
Operating Margin (TTM) Profitability N/A -202.5% Higher Margin DNA
Net Profit Margin Profitability N/A -192.0% Higher Margin DNA
Return on Equity (ROE) Capital Efficiency N/A -58.2% Higher ROE DNA
52-Week Range Position Momentum 90% ($28โ€“$37) 24% ($5โ€“$18) Stronger Trend MEDI
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 22% Vol 3.14ฮฒ ยท 152% Vol Lower Realized Risk MEDI
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 57.4 / 100 (HOLD) Higher Composite DNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MEDI vs DNA Buy Guide
MEDI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MEDI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DNA BREAKDOWN
30d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live DNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MEDI nor DNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.